title: Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.
abstract: Irisin is a myokine secreted by skeletal muscle during exercise. Abnormal serum irisin levels are associated with obesity and type 2 diabetes (T2D). This study investigated the changes in serum irisin in the obese patients with newly diagnosed T2D following glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide) treatment.
  
  
  
  Fifty-four obese patients with T2D were treated with exenatide for 12weeks. The control group included 54 age-, sex-, and body mass index (BMI)-matched subjects with normal glucose tolerance.
  
  
  
  Patients with T2D had lower irisin than the control group (38.06 [29.29-53.79] vs. 58.01 [43.07-87.79] ng/mL, P<0.01]. Serum irisin was negatively associated with BMI (r=-0.178, P<0.05), fasting blood glucose (FBG; r=-0.170, P<0.05), and glycosylated hemoglobin (HbA1c; r=-0.189, P<0.01) in patients with T2D. Exenatide treatment markedly increased serum irisin by 19.28ng/mL (12.59-25.98) compared to baseline (P<0.01). Increased irisin was significantly correlated with decreased FBG and HbA1c after exenatide treatment (FBG: r=-0.35; HbA1c: r=-0.37; both P<0.05).
  
  
  
  Exenatide treatment significantly increased irisin in patients with T2D. Post-treatment changes in irisin were correlated with decreases in FBG and HbA1c. The upregulation of irisin might be a novel mechanism for the beneficial effects of exenatide in type 2 diabetic patients.
authors: Department of Endocrinology; Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.
authors: Jia
authors: J
authors: Liu
authors: Department of Endocrinology; Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.
authors: Yanjin
authors: Y
authors: Hu
authors: Department of Endocrinology; Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.
authors: Heng
authors: H
authors: Zhang
authors: Department of Endocrinology; Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.
authors: Yuan
authors: Y
authors: Xu
authors: Department of Endocrinology; Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China. Electronic address: drwg6688@126.com.
authors: Guang
authors: G
authors: Wang
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D010455:Peptides / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*
chemical_list: C577593:FNDC5 protein, human; D005353:Fibronectins; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide
keywords: GLP-1 receptor agonist; Irisin; Myokine; Obesity; Type 2 diabetes